Enanta Capital Surpluse from 2010 to 2024

ENTA Stock  USD 12.78  0.13  1.01%   
Enanta Pharmaceuticals' Capital Surpluse is increasing over the years with slightly volatile fluctuation. Capital Surpluse is expected to dwindle to about 317.9 M. From 2010 to 2024 Enanta Pharmaceuticals Capital Surpluse quarterly data regression line had arithmetic mean of  295,946,615 and r-squared of  0.78. View All Fundamentals
 
Capital Surpluse  
First Reported
2013-03-31
Previous Quarter
405.5 M
Current Value
410.8 M
Quarterly Volatility
60.3 M
 
Yuan Drop
 
Covid
Check Enanta Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Enanta Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.9 M, Interest Expense of 3.1 M or Selling General Administrative of 63.9 M, as well as many indicators such as Price To Sales Ratio of 2.53, Dividend Yield of 0.0 or PTB Ratio of 1.92. Enanta financial statements analysis is a perfect complement when working with Enanta Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Enanta Pharmaceuticals Correlation against competitors.
For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.

Latest Enanta Pharmaceuticals' Capital Surpluse Growth Pattern

Below is the plot of the Capital Surpluse of Enanta Pharmaceuticals over the last few years. It is Enanta Pharmaceuticals' Capital Surpluse historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Enanta Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Capital Surpluse10 Years Trend
Slightly volatile
   Capital Surpluse   
       Timeline  

Enanta Capital Surpluse Regression Statistics

Arithmetic Mean295,946,615
Geometric Mean287,319,429
Coefficient Of Variation25.99
Mean Deviation63,526,390
Median276,526,000
Standard Deviation76,919,043
Sample Variance5916.5T
Range236.2M
R-Value0.88
Mean Square Error1399.6T
R-Squared0.78
Significance0.000013
Slope15,193,594
Total Sum of Squares82831.5T

Enanta Capital Surpluse History

2024317.9 M
2023457.7 M
2021398 M
2020351 M
2019327 M
2018298.4 M
2017276.5 M

About Enanta Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Enanta Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Enanta Pharmaceuticals investors use historical funamental indicators, such as Enanta Pharmaceuticals's Capital Surpluse, to determine how well the company is positioned to perform in the future. Although Enanta Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Enanta Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Enanta Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Enanta Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Enanta Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capital Surpluse457.7 M317.9 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Information and Resources on Investing in Enanta Stock

When determining whether Enanta Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enanta Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enanta Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enanta Pharmaceuticals Stock:
Check out the analysis of Enanta Pharmaceuticals Correlation against competitors.
For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.
You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enanta Pharmaceuticals. If investors know Enanta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enanta Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.66)
Earnings Share
(6.25)
Revenue Per Share
3.455
Quarterly Revenue Growth
(0.04)
Return On Assets
(0.23)
The market value of Enanta Pharmaceuticals is measured differently than its book value, which is the value of Enanta that is recorded on the company's balance sheet. Investors also form their own opinion of Enanta Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Enanta Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enanta Pharmaceuticals' market value can be influenced by many factors that don't directly affect Enanta Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enanta Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enanta Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enanta Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.